Product: IFNB1 Antibody
Catalog: DF6471
Description: Rabbit polyclonal antibody to IFNB1
Application: WB IHC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 22kDa; 22kD(Calculated).
Uniprot: P01574
RRID: AB_2838433

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
IFNB1 Antibody detects endogenous levels of total IFNB1.
RRID:
AB_2838433
Cite Format: Affinity Biosciences Cat# DF6471, RRID:AB_2838433.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

beta-interferon; Fibroblast interferon; IFB; IFF; IFN beta; IFN-beta; IFNB 1; IFNB; IFNB_HUMAN; IFNB1; Interferon beta 1 fibroblast; Interferon beta; Interferon beta precursor; MGC96956;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Description:
The genes encoding type I interferons (IFNs), which include 14 IFN- genes, one IFN-∫ gene, one IFN-w (also known as IFN- II1) gene, and a number of IFN-w pseudogenes, are clustered on human chromosome 9. Interferons- and -∫ are cytokines that are widely known to induce potent antiviral activity. IFN- and -∫ exert a variety of other biological effects, including antitumor and immunomodulatory activities and are increasingly used clinically to treat a range of malignancies, myelodysplasias and autoimmune diseases. IFN-w is antigenically different from human IFN- , IFN-∫ or IFN- , but is a component of natural mixtures of IFN species produced by virus-induced leukocytes or Burkitt's lymphoma cells. The type I interferon receptor (IFN- R) interacts with IFN- , IFN-∫ and IFN-w, and seems to be a multisubunit receptor.
Sequence:
MTNKCLLQIALLLCFSTTALSMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN

PTMs - P01574 As Substrate

Site PTM Type Enzyme
S140 Phosphorylation

Research Backgrounds

Function:

Has antiviral, antibacterial and anticancer activities.

Subcellular Location:

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Monomer. Signals mostly via binding to a IFNAR1-IFNAR2 heterodimeric receptor, but can also function with IFNAR1 alone and independently of Jak-STAT pathways.

Family&Domains:

Belongs to the alpha/beta interferon family.

Research Fields

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Cytosolic DNA-sensing pathway.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

References

1). Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer’s disease. Journal of Neuroinflammation (PubMed: 35971179) [IF=9.3]

Application: WB    Species: Mouse    Sample: HT22 cells

Fig. 2Hyperphosphorylated tau induces cytokine upregulation. A Differentially expressed genes (DEGs) between HT22 cells transfected with vector or TauP301S for 48 h. B Analysis of DEGs in the TauP301S and Tau groups according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. C Heat map of cytokine genes differentially expressed in HT22 cells transfected with vector or Tau or TauP301S following treatment with DMSO or Nec-1 (30 μM); low expression is shown in blue and high expression in red. D mRNAs from HT22 cells transfected with vector or TauP301S following treatment with DMSO or Nec-1 (30 μM) were extracted and quantified to determine indicated cytokine levels by qPCR. E Cytokine levels in HT22 cells transfected with vector or TauP301S following treatment with DMSO or Nec-1 (30 μM) were analyzed by western blotting with the indicated antibodies. F ROS levels in HT22 cells transfected with vector or TauP301S. G Chemotaxis of pTau-induced cytokines on BV2 cells was analyzed by transwell assays, Scale bars, 100 μm. Data are presented as the mean ± standard error of the mean (SEM) of three experiments, and statistical analysis was performed using one-way ANOVA with Dunnett’s multiple comparisons test in D and two-tailed unpaired t test in F, G

2). Tongmai granules improve rat hippocampal injury by regulating TLR4/MyD88/AP-1 signaling pathway. JOURNAL OF ETHNOPHARMACOLOGY (PubMed: 34838942) [IF=5.4]

3). Effects of acute endurance exercise and exhaustive exercise on innate immune signals induced by mtDNA. European Journal of Inflammation [IF=0.7]

Application: WB    Species: Mouse    Sample: liver

Figure 3. Effects of acute exercise of different intensity on TLR9 and cGAS/STING signaling in liver, spleen, and leukocytes. (a, b, c) Effects of acute exercise of different intensity on mRNA expression of TLR9 and cGAS/STING signaling related molecules in liver (a), spleen (b), and leukocytes (c) (n = 6). Expression was normalized to 18S RNA. (d, e, f) Effects of acute exercise of different intensity on protein expression of TLR9 and cGAS/STING signaling related molecules in liver (d), spleen (e), and leukocytes (f) (n = 6). Expression was normalized to 18S RNA. (g, h) Effects of different intensity of acute exercise on plasma levels of IFN-β (g) and IL-6 (h) (n = 6). The density of each band was normalized to β-actin.

4). Mesenchymal Stem Cells Carrying IFN-α and IFN-β Overexpression Genes Inhibit Non-Small Cell Lung Cancer via the JAK/STAT Pathway. Journal of Evolutionary Biochemistry and Physiology [IF=0.6]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.